Alzheimer. Alzheimer disease
Conditions
Interventions
Intervention 1: Group of Patients is treated randomly with quetiapine alone, 12.5 mgr in night and rise to 25 to 50 mg according to patient condition. Intervention 2: Group of Patients is treated rand
Treatment - Drugs
Prevention
Placebo
Diagnosis
Group of Patients is treated randomly with quetiapine alone, 12.5 mgr in night and rise to 25 to 50 mg according to patient condition
Group of Patients is treated randomly with risperidone alone, 0.5 mgr in night and rise to 1 to 2 mg daily according to patient condition.
Group of Patients Divided into two groups, one group received quetiapine combined with a cobalamin 500 mg daily.
Group risperidone of Patients Divided into two groups,second group received risperidone combined with a cobalamin 500 mg daily.
Patients who take risperidone. another group received placebo with risperidone
Patients who take quetiapine. another group received placebo with quetiapine.
Serum levels of IL-6, IL-8 and TNF-a, as pro-inflammatory cytokines, in all participants will be evaluated using ELISA method in a serum samples. Serum samples were collected from a coagulated blood a
Sponsors
Rafsanjan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
64 Years to 84 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria In this study is: (Alzheimer diagnosis in elderly patients is carried out on basis of clinical interviews; DSM IV diagnosis criteria; medical history; clinical examinations; MRI and brain CT scan results and the mini mental state examination score; Patients who have mini mental score above than are studied; patient with Brief Psychiatric Rating Scale score 30-70) Exclusion criteria (Patients who were taking anti-psychotic medication; has schizophrenia symptoms; preliminary psychotic disorders; delirium; psychoses followed by drug or medication take; Other medical background disorders like B12 deficiency and hypothyroidism; Patients needed to be hospitalized; Patients posed to suicide commitment risk; Other causes of dementia like brain tumors; strokes; normal pressure hydrocephalus; Underlying medical conditions; that may cause behavioral or psychotic symptoms or delirium such as infection, medications with anticholinergic effects; corticosteroid use; or neurological insults is the first step in the decision-making process for treatment. In addition, the patients were discarded from the procedure if they need further medical intervention and other drugs according to their health status or families’ remark.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: 2week,4week,8week. Method of measurement: Visual Analogue Scale For Pain Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Psychiatric symptoms. Timepoint: Before treatment , 2 weeks and 8 weeks after treatment. Method of measurement: Brief Psychiatric Rating Scale Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Reza Vakilin
Rafsanjan University of Medical Sciences
Outcome results
None listed